ALBI-FIB4
Prediction of hepatic decompensation in patient with compensated liver disease, using the ALBI-FIB4 score
The progression of chronic liver disease (CLD), from fibrosis to clinical outcomes, and clinical sequelae including liver decompensation (ascites, variceal bleeding and encephalopathy) manifest relatively late in the natural history and are often the index presentation of liver disease. Using a combination of ALBI and FIB-4 scores, we present here a model [developed in a prospectively accrued cohort [( and validated in two independent international cohorts (Europe and the Middle East)], that identifies patients as being at low or high risk of decompensation. The ALBI-FIB4 score identified the high risk group more effectively than the MELD score and maintained performance in cohorts with distinct differences in aetiology of cirrhosis. In the prospective cohort, the risk of decompensation was 7 times greater in the high risk group compared to the low risk group. Using routinely available clinical laboratory tests, the model is likely to be globally applicable.
Primary reference:
Guha I. et al., Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. Clin Gastroenterol Hepatol. 2019, (7):2330-2338.